Skip to content
Comparisons

LunaRx vs. Nurx: GLP-1 Telehealth Compared

A side-by-side of pricing, access, and clinical support between LunaRx and Nurx.

9 min readWritten and fact-checked against the sources below

Disclosure

The GLP Journal is published by LunaRx, so this comparison is written with that conflict disclosed. We aim for accuracy, not advocacy. Compounded GLP-1s are not FDA-approved, and since the 2025 shortage delistings they can only be dispensed in narrow, patient-specific circumstances. This is not medical advice.

LunaRx and Nurx both offer GLP-1 telehealth. The difference is in care model, access, and how each handles the coming-off question.

Side by side
LunaRxNurx
ModelPhysician-led, clinician sets planConsumer telehealth, app-first
SupplyCompounded, via 503A and 503B partner facilitiesCompounded and/or brand, varies
Differentiator'Come off clean' focusConvenience, price point
PricingTiered; itemizeMonthly; varies

Should you choose LunaRx or Nurx?

  • LunaRx — if you want a clinician setting your plan and an explicit taper/exit strategy.
  • Nurx — if you want a consumer-friendly brand with a lower entry price point.

What should you verify with LunaRx and Nurx?

  • Is this the FDA-approved product or a compounded one? If compounded, what clinically significant difference has the prescriber documented for you? Since the 2025 shortage delistings that documentation is what the remaining exception turns on.
  • Total monthly cost including shipping and any fees.
  • What happens to your plan and price if you stop.

Bottom line

Both are legitimate telehealth options with different models. LunaRx leans clinician-led with an explicit coming-off focus; Nurx leans consumer convenience and price. We disclose we publish this comparison. Verify pricing and fit — this is information, not a recommendation.

Sources

Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.

  1. 1.
    FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize

    U.S. Food and Drug Administration · 2025

    Shortages resolved (tirzepatide December 2024, semaglutide February 2025) and the compounding enforcement deadlines that followed.

  2. 2.
    Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A

    U.S. Food and Drug Administration, guidance for industry · 2018

    A 503A pharmacy may not compound, regularly or in inordinate amounts, a drug that is essentially a copy of a commercially available product. Patient-specific compounding remains possible where the prescriber documents a clinically significant difference for that patient.

  3. 3.
    FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List

    U.S. Food and Drug Administration · 2026

    April 2026 proposal to exclude these molecules from the 503B bulk drug substances list.

Get the weekly research update

New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.

Unsubscribe anytime. Read our privacy policy.

Related in Comparisons